Universidad Peruana Cayetano Heredia
Antiepileptic drug therapy and recommendations for withdrawal in patients with seizures and epilepsy due to neurocysticercosis
JavaScript is disabled for your browser. Some features of this site may not work without it.
Mostrar el registro sencillo del ítem
| dc.contributor.author | Bustos Palomino, Javier Arturo | |
| dc.contributor.author | García Lescano, Héctor Hugo | |
| dc.contributor.author | Del-Brutto, Oscar-H. | |
| dc.date.accessioned | 2019-02-06T14:51:17Z | |
| dc.date.available | 2019-02-06T14:51:17Z | |
| dc.date.issued | 2016 | |
| dc.identifier.uri | https://hdl.handle.net/20.500.12866/5196 | |
| dc.description.abstract | INTRODUCTION: Neurocysticercosis (NCC) is a leading causes of secondary epilepsy worldwide. There is increasing evidence on the epileptogenic role of NCC, and the presence of edema, calcified scars, gliosis and hippocampal sclerosis support this phenomenon. AREAS COVERED: We summarized principles of antiepileptic drug (AED) therapy as well as risk factors associated with seizure recurrence after AED withdrawal in patients with NCC. Expert commentary: First-line AED monotherapy is effective as a standard approach to control seizures in most NCC patients. Risks and benefits of AED withdrawal have not been systematically studied, and this decision must be individualized. However, a seizure-free period of at least two years seem prudent before attempting withdrawal. Risk factors for seizure recurrence after AED withdrawal include a history of status epilepticus, poor seizure control during treatment, neuroimaging evidence of perilesional gliosis, hippocampal sclerosis and calcified lesions, as well as persistence of paroxysmal activity in the EEG. | en_US |
| dc.language.iso | eng | |
| dc.publisher | Taylor and Francis | |
| dc.relation.ispartofseries | Expert Review of Neurotherapeutics | |
| dc.rights | info:eu-repo/semantics/restrictedAccess | |
| dc.rights.uri | https://creativecommons.org/licenses/by-nc-nd/4.0/deed.es | |
| dc.subject | antiepileptic drug withdrawal | en_US |
| dc.subject | cysticercosis | en_US |
| dc.subject | epilepsy | en_US |
| dc.subject | Neurocysticercosis | en_US |
| dc.subject | seizures | en_US |
| dc.subject | Anticonvulsants/therapeutic use | en_US |
| dc.subject | Epilepsy/drug therapy/etiology | en_US |
| dc.subject | Humans | en_US |
| dc.subject | Neurocysticercosis/complications | en_US |
| dc.subject | Neuroimaging | en_US |
| dc.subject | Recurrence | en_US |
| dc.subject | Seizures/drug therapy/etiology | en_US |
| dc.subject | Withholding Treatment | en_US |
| dc.title | Antiepileptic drug therapy and recommendations for withdrawal in patients with seizures and epilepsy due to neurocysticercosis | en_US |
| dc.type | info:eu-repo/semantics/review | |
| dc.identifier.doi | https://doi.org/10.1080/14737175.2016.1194757 | |
| dc.subject.ocde | https://purl.org/pe-repo/ocde/ford#3.01.04 | |
| dc.subject.ocde | https://purl.org/pe-repo/ocde/ford#3.01.05 | |
| dc.relation.issn | 1744-8360 |
Ficheros en el ítem
| Ficheros | Tamaño | Formato | Ver |
|---|---|---|---|
|
No hay ficheros asociados a este ítem. |
|||
Este ítem aparece en la(s) siguiente(s) colección(ones)
-
Artículos en revistas indizadas [4988]
Recuperados de bases de datos bibliográficas
Excepto si se señala otra cosa, la licencia del ítem se describe como info:eu-repo/semantics/restrictedAccess
